MX2007006102A - Agentes anti-cancer de union a tubulina y profarmacos de los mismos. - Google Patents
Agentes anti-cancer de union a tubulina y profarmacos de los mismos.Info
- Publication number
- MX2007006102A MX2007006102A MX2007006102A MX2007006102A MX2007006102A MX 2007006102 A MX2007006102 A MX 2007006102A MX 2007006102 A MX2007006102 A MX 2007006102A MX 2007006102 A MX2007006102 A MX 2007006102A MX 2007006102 A MX2007006102 A MX 2007006102A
- Authority
- MX
- Mexico
- Prior art keywords
- tubulin binding
- prodrugs
- cancer agents
- anti cancer
- binding anti
- Prior art date
Links
- 102000004243 Tubulin Human genes 0.000 title abstract 3
- 108090000704 Tubulin Proteins 0.000 title abstract 3
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 239000000651 prodrug Substances 0.000 title abstract 2
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63042204P | 2004-11-22 | 2004-11-22 | |
| US72692805P | 2005-10-14 | 2005-10-14 | |
| PCT/US2005/042095 WO2006057946A2 (en) | 2004-11-22 | 2005-11-17 | Tubulin binding anti cancer agents and prodrugs thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007006102A true MX2007006102A (es) | 2007-07-11 |
Family
ID=36498450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007006102A MX2007006102A (es) | 2004-11-22 | 2005-11-17 | Agentes anti-cancer de union a tubulina y profarmacos de los mismos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090042820A1 (enExample) |
| EP (1) | EP1819338A4 (enExample) |
| JP (1) | JP2008520719A (enExample) |
| KR (1) | KR20070086595A (enExample) |
| AU (1) | AU2005309761A1 (enExample) |
| CA (1) | CA2587210A1 (enExample) |
| IL (1) | IL183212A0 (enExample) |
| MX (1) | MX2007006102A (enExample) |
| NO (1) | NO20073211L (enExample) |
| WO (1) | WO2006057946A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
| CN102746336B (zh) | 2005-06-29 | 2015-08-19 | 施瑞修德制药公司 | 氨基磷酸酯烷化剂前体药物 |
| KR20090025367A (ko) * | 2006-06-28 | 2009-03-10 | 가부시키가이샤산와카가쿠켄큐쇼 | 신규 6-5계 이환식 복소환 유도체 및 그 의약용도 |
| EP2114157B1 (en) | 2006-12-26 | 2021-05-26 | ImmunoGenesis, Inc. | Phosphoramidate alkylator prodrug for the treatment of cancer |
| US8765690B2 (en) | 2007-04-05 | 2014-07-01 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with glufosfamide in patients not receiving insulin therapy |
| WO2008151253A1 (en) * | 2007-06-04 | 2008-12-11 | Threshold Pharmaceuticals, Inc. | Hypoxia activated prodrugs of antineoplastic agents |
| WO2010048330A1 (en) | 2008-10-21 | 2010-04-29 | Threshold Pharmaceuticals, Inc. | Treatment of cancer using hypoxia activated prodrugs |
| FR2962437B1 (fr) * | 2010-07-06 | 2012-08-17 | Sanofi Aventis | Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique |
| US9487506B2 (en) | 2011-04-13 | 2016-11-08 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
| WO2014069063A1 (ja) | 2012-10-29 | 2014-05-08 | 京セラ株式会社 | 弾性表面波センサ |
| CA2924843A1 (en) * | 2013-09-27 | 2015-04-02 | Allergan, Inc. | Compounds and methods for skin repair |
| EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| US9493450B2 (en) | 2014-02-13 | 2016-11-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| PE20161573A1 (es) | 2014-02-13 | 2017-01-19 | Incyte Corp | Ciclopropilamina como inhibidor de la lsd1 |
| WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016011195A1 (en) | 2014-07-17 | 2016-01-21 | Threshold Pharmaceuticals, Inc. | Th-302 solid forms and methods related thereto |
| CN107530556B (zh) | 2015-03-10 | 2020-04-10 | 深圳艾欣达伟医药科技有限公司 | Dna烷化剂 |
| US10829437B2 (en) * | 2015-04-02 | 2020-11-10 | Obi Pharma, Inc. | Nitrobenzyl derivatives of anti-cancer agents |
| PE20180455A1 (es) | 2015-04-03 | 2018-03-05 | Incyte Corp | Compuestos heterociclicos como inhibidores de lsd1 |
| CA2990665A1 (en) | 2015-06-24 | 2016-12-29 | Threshold Pharmaceuticals, Inc. | Aziridine containing dna alkylating agents |
| SG10202001219UA (en) | 2015-08-12 | 2020-03-30 | Incyte Corp | Salts of an lsd1 inhibitor |
| CN109414410B (zh) | 2016-04-22 | 2022-08-12 | 因赛特公司 | Lsd1抑制剂的制剂 |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| US11427591B2 (en) | 2018-10-17 | 2022-08-30 | Insilico Medicine Ip Limited | Kinase inhibitors |
| CN115403483B (zh) * | 2021-07-02 | 2024-01-26 | 河南省儿童医院郑州儿童医院 | 含二苯乙烯或二苯甲酮骨架的ca-4衍生物、药物组合物及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004099139A1 (en) * | 2000-09-15 | 2004-11-18 | Baylor University | Indole-containing compounds with anti-tubulin and vascular targeting activity |
| DE60129536T2 (de) * | 2000-03-10 | 2008-06-19 | Baylor University, Waco | Tubulin bindende liganden |
| FR2816938B1 (fr) * | 2000-11-22 | 2003-01-03 | Sanofi Synthelabo | Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant |
| FR2838123B1 (fr) * | 2002-04-04 | 2005-06-10 | Sanofi Synthelabo | Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf |
| FR2839718B1 (fr) * | 2002-05-17 | 2004-06-25 | Sanofi Synthelabo | Derives d'indole, leur procede de preparation et les compositions pharmaceutiques en contenant |
| DE60336646D1 (de) * | 2003-08-07 | 2011-05-19 | Nat Health Research Institutes | Indol-Verbindungen als Inhibitoren der Tubulin-Polymerisation zur Behandlung von angiogenesisbezogenen Erkrankungen |
| US7456289B2 (en) * | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
-
2005
- 2005-11-17 AU AU2005309761A patent/AU2005309761A1/en not_active Abandoned
- 2005-11-17 MX MX2007006102A patent/MX2007006102A/es not_active Application Discontinuation
- 2005-11-17 KR KR1020077014342A patent/KR20070086595A/ko not_active Withdrawn
- 2005-11-17 WO PCT/US2005/042095 patent/WO2006057946A2/en not_active Ceased
- 2005-11-17 JP JP2007543334A patent/JP2008520719A/ja not_active Withdrawn
- 2005-11-17 EP EP05826480A patent/EP1819338A4/en not_active Withdrawn
- 2005-11-17 CA CA002587210A patent/CA2587210A1/en not_active Abandoned
- 2005-11-17 US US11/791,420 patent/US20090042820A1/en not_active Abandoned
-
2007
- 2007-05-15 IL IL183212A patent/IL183212A0/en unknown
- 2007-06-22 NO NO20073211A patent/NO20073211L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070086595A (ko) | 2007-08-27 |
| WO2006057946A3 (en) | 2007-07-05 |
| JP2008520719A (ja) | 2008-06-19 |
| IL183212A0 (en) | 2008-04-13 |
| CA2587210A1 (en) | 2006-06-01 |
| WO2006057946A2 (en) | 2006-06-01 |
| NO20073211L (no) | 2007-08-21 |
| EP1819338A4 (en) | 2009-11-04 |
| US20090042820A1 (en) | 2009-02-12 |
| AU2005309761A1 (en) | 2006-06-01 |
| EP1819338A2 (en) | 2007-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007006102A (es) | Agentes anti-cancer de union a tubulina y profarmacos de los mismos. | |
| IL180677A0 (en) | Compounds, compositions and methods for treatment of hyperproliferative diseases, such as cancer | |
| PL1874821T3 (pl) | Kombinacja przeciwciał i glikokortykoidów do leczenia raka | |
| IL241756A0 (en) | Preparations and methods for the treatment of diseases of safty tumors | |
| WO2006128129A3 (en) | Method for treating cancer | |
| IL180729A0 (en) | Compounds and methods for treatment of cancer | |
| WO2007053573A3 (en) | Treatment of cancer with sorafenib | |
| IL187238A0 (en) | Compositions and methods for treating hyperproliferative epidermal diseases | |
| BRPI0519424A2 (pt) | composiÇÕes e mÉtodos para tratamento de distérbios de proliferaÇço celular | |
| IL176919A0 (en) | Methods and compositions for treating cancer | |
| WO2007101148A3 (en) | Hexose compounds to treat cancer | |
| IL178920A0 (en) | Treatment for pancreatic cancer | |
| IL189377A0 (en) | Combinations comprising dmxaa for the treatment of cancer | |
| IL189376A0 (en) | Combinations comprising dmxaa for the treatment of cancer | |
| IL177104A (en) | Ccx-ckr2 binding agents for treatment of cancer and arthritis and for wound healing | |
| IL161899A0 (en) | Kit for treatment of cancer | |
| EP1855662A4 (en) | METHODS AND COMPOSITIONS FOR TREATING CANCER | |
| WO2007137196A3 (en) | Tubulin binding anti cancer compounds and prodrugs thereof | |
| GB0410379D0 (en) | Treatment of cancer | |
| ZA200704901B (en) | Tubulin binding anti cancer agents and prodrugs thereof | |
| HK1109060A (en) | Combinations of therapeutic agents for treating cancer | |
| GB0423273D0 (en) | Treatment of cancer | |
| HK1097275A (en) | Compounds and methods for treatment of cancer | |
| GB0404571D0 (en) | Methods for treating interstitial cystitis and related compounds and compositions | |
| HK1110303A (en) | Methods and compositions for treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |